GGrantIndex
← Leaderboards

Christopher James Donnelly

University Of Pittsburgh At Pittsburgh

Google Scholar ↗PubMed ↗ORCID ↗
$6,743,962
Attributed
$16,934,406
Total exposure
9
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.9M · FY2017–25
$10M$7.5M$5M$2.5M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,934,406 · 9

By mechanism

R01$10,925,267 · 2
RF1$3,360,074 · 1
R21$2,109,011 · 5
T32$540,054 · 1

Top collaborators

Most similar at University Of Pittsburgh At Pittsburgh

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Protein Tdp-43”

Research focus

Protein Tdp-43Amyotrophic Lateral SclerosisCellsNeuronsNeurodegenerative DisordersPathologicBiological ModelsNeuropathologyInduced Pluripotent Stem CellGeneticPreventGenesNeurotoxicityPathogenesisMotor NeuronsTissuesProteinsMediatingMutationCytoplasmExhibitsIn VivoExperimental StudyFrontotemporal Dementia

Grant awards (22)

Defining short RNA therapeutics that combat TDP-43 proteinopathy connected to AD and ADRDs.$3,360,074
RF1 · FY2025 · AG
Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND$1,752,943
R01 · FY2025 · NS · contact PI
Training in the Neurobiology of Neurological Disease$540,054
T32 · FY2025 · NS · contact PI
Peptide Nucleic Acid (PNA) Oligomers for Targeted Disruption of Biomolecular Condensates in ALS/FTD$232,953
R21 · FY2025 · NS
Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND$1,818,953
R01 · FY2024 · NS · contact PI
Peptide Nucleic Acid (PNA) Oligomers for Targeted Disruption of Biomolecular Condensates in ALS/FTD$194,809
R21 · FY2024 · NS
Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND$2,054,384
R01 · FY2023 · NS · contact PI
Axonal TDP-43 Dysregulation in ALS and Dementia$407,758
R21 · FY2023 · NS · contact PI
Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND$1,662,271
R01 · FY2022 · NS · contact PI
An optogenetic approach to establish the interplay between stress granules and TDP-43 proteinopathy in ALS/FTD$372,163
R01 · FY2022 · NS · contact PI
Identification of TDP-43 modifiers through single-cell transcriptional and epigenomic dissection of ALS and FTLD-MND$1,817,770
R01 · FY2021 · NS · contact PI
An optogenetic approach to establish the interplay between stress granules and TDP-43 proteinopathy in ALS/FTD$372,719
R01 · FY2021 · NS · contact PI
An optogenetic approach to establish the interplay between stress granules and TDP-43 proteinopathy in ALS/FTD$373,258
R01 · FY2020 · NS · contact PI
Oligonucleotide approach to antagonize neurotoxic TDP-43 assemblies in dementia$188,892
R21 · FY2020 · AG · contact PI
An optogenetic approach to establish the interplay between stress granules and TDP-43 proteinopathy in ALS/FTD$327,060
R01 · FY2019 · NS · contact PI
Oligonucleotide approach to antagonize neurotoxic TDP-43 assemblies in dementia$228,181
R21 · FY2019 · AG · contact PI
An optogenetic approach to establish the interplay between stress granules and TDP-43 proteinopathy in ALS/FTD$46,722
R01 · FY2019 · NS · contact PI
An optogenetic approach to establish the interplay between stress granules and TDP-43 proteinopathy in ALS/FTD$327,024
R01 · FY2018 · NS · contact PI
Nuclear export inhibition as a novel therapeutic target for C9ORF72 ALS/FTD$195,625
R21 · FY2018 · NS · contact PI
Molecular mechanisms of C9orf72 and Matrin 3 interaction in ALS$195,104
R21 · FY2018 · NS
Nuclear export inhibition as a novel therapeutic target for C9ORF72 ALS/FTD$233,376
R21 · FY2017 · NS · contact PI
Molecular mechanisms of C9orf72 and Matrin 3 interaction in ALS$232,313
R21 · FY2017 · NS